Table 2 Characteristics of medications use depending on the presence or the absence of metabolic syndrome
| Parameters | Men | Women | ||
|---|---|---|---|---|
| MS + (n = 36) | MS - (n = 33) | MS + (n = 47) | MS - (n = 28) | |
| ACEI, n (%) | 5 (15,2) | 3 (8,3) | 8 (28,6) | 4 (8,5)* |
| Amlodipine, n (%) | 0 (0) | 1 (2,8) | 1 (3,6) | 1 (2,1) |
| Other Ca antagonists (Verapamil, Nifedipine), n (%) | 1 (3,03) | 0 (0) | 1 (3,6) | 0 (0) |
| Beta blockers (atenolol), n (%) | 3 (9,1) | 2 (5,6) | 1 (3,6) | 3 (6,4) |
| Indapamide, n (%) | 1 (3,03) | 0 (0) | 0 (0) | 0 (0) |
| Oral glucose lowering drug (glibenclamide), n (%) | 2 (6,1) | 0 (0) | 1 (3,6) | 0 (0) |